scholarly journals New way, new recommendation: Individualized treatment of novel antidiabetic drugs for people living with type 2 diabetes based on the cardiorenal risks

2021 ◽  
Author(s):  
Xiang Xu ◽  
Yan Bi
Keyword(s):  
Type 2 Diabetes ◽  
Antidiabetic Drugs ◽  
Individualized Treatment

scholarly journals Cost-effectiveness study of antidiabetic drugs in type 2 diabetes mellitus patients from Mumbai, India

2017 ◽  
Vol 4 (9) ◽  
pp. 3180 ◽  
Author(s):  
Dnyanesh Limaye ◽  
Krishna Todi ◽  
Jay Shroff ◽  
Ashutosh Ramaswamy ◽  
Priyanka Kulkarni ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cross Sectional Study ◽  
Antidiabetic Drugs ◽  
Cross Sectional ◽  
Validated Questionnaire ◽  
The Cost

Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India.Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5). Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness. 

scholarly journals SODIUM-GLUCOSE LINKED COTRANSPORTER 2 INHIBITOR: A NEW HORIZON IN THE TREATMENT OF TYPE-2 DIABETES

2021 ◽  
pp. 45-48
Author(s):  
REKHA BISHT
Keyword(s):  
Type 2 Diabetes ◽  
Adverse Effects ◽  
Antidiabetic Drugs ◽  
Diabetic Patients ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Sodium Glucose Cotransporter ◽  
Glucose Reabsorption ◽  
Glycemic Targets

Hyperglycemia is a key therapeutic focus in the management of patients with type 2 diabetes (T2D) mellitus. The various therapeutic classes of antidiabetic drugs presently existing in the market are not sufficiently effective in maintaining long-term glycemic control in most of the diabetic patients, even when used in combination. The undesirable adverse effects of these drugs, such as hypoglycemia, weight gain, and hepatic and renal toxicity, have escalated the demand for the discovery of new and safer antidiabetic drugs. The progressive nature of T2D requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic targets are not attained. Sodium-glucose cotransporter 2 inhibitors (SGLT2-is) are the new class of antidiabetic medications that are approved (2013) by the Food and Drug Administration recently for treating diabetes. These inhibitors block the SGLT2 protein involved in glucose reabsorption from the proximal renal tubule resulting in escalated glucose excretion and lower blood glucose levels. These inhibitors exhibit favorable effects beyond glucose control, such as consistent body weight, blood pressure, and serum uric acid reductions. This review highlighted the brief updates of SGLT2-i, their benefits, and adverse effects.

Adding Noninsulin Antidiabetic Drugs to Metformin Therapy for Type 2 Diabetes—Reply

JAMA ◽  
2010 ◽  
Vol 304 (4) ◽  
pp. 405
Author(s):  
Craig I. Coleman ◽  
Olivia J. Phung ◽  
Jennifer M. Scholle
Keyword(s):  
Type 2 Diabetes ◽  
Antidiabetic Drugs ◽  
Metformin Therapy

scholarly journals Economic impact of dapagliflozin vs. Other antidiabetic drugs for the treatment of patients with type 2 diabetes

2015 ◽  
Vol 18 (3) ◽  
pp. A59
Author(s):  
J. Lin ◽  
P. Dhankhar ◽  
K. Bell ◽  
J. Chhatwal ◽  
M. Lingohr-Smith
Keyword(s):  
Type 2 Diabetes ◽  
Economic Impact ◽  
Antidiabetic Drugs
Sign in / Sign up

Export Citation Format

Share Document